NO20064986L - Krystallin Pyrazolderivater - Google Patents

Krystallin Pyrazolderivater

Info

Publication number
NO20064986L
NO20064986L NO20064986A NO20064986A NO20064986L NO 20064986 L NO20064986 L NO 20064986L NO 20064986 A NO20064986 A NO 20064986A NO 20064986 A NO20064986 A NO 20064986A NO 20064986 L NO20064986 L NO 20064986L
Authority
NO
Norway
Prior art keywords
pyrazole derivatives
crystalline
crystalline pyrazole
benzenesulfonamide
pyrazol
Prior art date
Application number
NO20064986A
Other languages
English (en)
Inventor
Changquan Calvin Sun
Garry O'connor
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20064986L publication Critical patent/NO20064986L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W16/00—Network planning, e.g. coverage or traffic planning tools; Network deployment, e.g. resource partitioning or cells structures
    • H04W16/18—Network planning tools
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W24/00—Supervisory, monitoring or testing arrangements
    • H04W24/02—Arrangements for optimising operational condition

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse krystallformer av 4-[5-(4-fluorfenyl)-3-(trifluormetyl)-lH-pyrazol-l-yl]-benzensulfonamid og fremgangsmåter for fremstilling, mellomomdanning og isolering av slike krystaller.
NO20064986A 2004-04-01 2006-10-31 Krystallin Pyrazolderivater NO20064986L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55846904P 2004-04-01 2004-04-01
PCT/IB2005/000735 WO2005095349A1 (en) 2004-04-01 2005-03-21 Crystalline pyrazole derivative

Publications (1)

Publication Number Publication Date
NO20064986L true NO20064986L (no) 2006-12-21

Family

ID=34961629

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064986A NO20064986L (no) 2004-04-01 2006-10-31 Krystallin Pyrazolderivater

Country Status (24)

Country Link
US (2) US7652149B2 (no)
EP (1) EP1742922B1 (no)
JP (1) JP4177883B2 (no)
KR (1) KR100820511B1 (no)
CN (1) CN1938276B (no)
AR (1) AR048449A1 (no)
AU (1) AU2005227745C1 (no)
BR (1) BRPI0509506A8 (no)
CA (1) CA2562104C (no)
DK (1) DK1742922T3 (no)
EA (1) EA008697B1 (no)
ES (1) ES2565409T3 (no)
HU (1) HUE028811T2 (no)
IL (1) IL177711A0 (no)
MA (1) MA28494B1 (no)
NO (1) NO20064986L (no)
NZ (1) NZ550907A (no)
PL (1) PL1742922T3 (no)
SI (1) SI1742922T1 (no)
TN (1) TNSN06313A1 (no)
TW (1) TW200536816A (no)
UA (1) UA84455C2 (no)
WO (1) WO2005095349A1 (no)
ZA (1) ZA200607154B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028811T2 (en) * 2004-04-01 2017-01-30 Zoetis Services Llc Crystalline pyrazole derivative
WO2007069254A2 (en) 2005-12-14 2007-06-21 Makhteshim Chemical Works Ltd. POLYMORPHS AND AMORPHOUS FORMS OF 5-AMINO-l-[2,6- DICHLORO-4-(TRIFLUOROMETHYL)PHENYL]-4- [(TRIFLUOROMETHYL)SULFINYL]-IH-PYRAZOLE-3-CARBONITRILE
UA110598C2 (uk) 2006-11-10 2016-01-25 Басф Се Спосіб одержання кристалічної модифікації фіпронілу
US8791046B2 (en) 2006-11-10 2014-07-29 Basf Se Crystalline modification of fipronil
JP5931322B2 (ja) 2006-11-10 2016-06-08 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ フィプロニルの結晶変態
JP2017081860A (ja) * 2015-10-29 2017-05-18 株式会社トクヤマ セレコキシブの製造方法
CN115246790A (zh) * 2021-04-25 2022-10-28 广东东阳光药业有限公司 一种吡唑类化合物的晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69112917T2 (de) * 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US6492411B1 (en) * 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
KR19990064310A (ko) * 1995-10-17 1999-07-26 윌리암스 로저 에이 시클로옥시게나제-2의 검출방법
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6221153B1 (en) * 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
TR200001872A2 (tr) * 2000-06-26 2002-01-21 Fako �La�Lari A.� 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine ilişkin yöntem.
HUE028811T2 (en) * 2004-04-01 2017-01-30 Zoetis Services Llc Crystalline pyrazole derivative

Also Published As

Publication number Publication date
UA84455C2 (en) 2008-10-27
IL177711A0 (en) 2006-12-31
PL1742922T3 (pl) 2016-06-30
TNSN06313A1 (fr) 2007-12-03
KR100820511B1 (ko) 2008-04-11
HUE028811T2 (en) 2017-01-30
AU2005227745C1 (en) 2009-02-26
KR20060131949A (ko) 2006-12-20
EP1742922A1 (en) 2007-01-17
AR048449A1 (es) 2006-04-26
CN1938276B (zh) 2011-08-10
HK1099755A1 (en) 2007-08-24
JP2007530655A (ja) 2007-11-01
CA2562104A1 (en) 2005-10-13
AU2005227745A1 (en) 2005-10-13
ZA200607154B (en) 2008-03-26
US20050222240A1 (en) 2005-10-06
US7652149B2 (en) 2010-01-26
JP4177883B2 (ja) 2008-11-05
BRPI0509506A8 (pt) 2017-01-24
AU2005227745B2 (en) 2008-05-29
NZ550907A (en) 2010-10-29
TW200536816A (en) 2005-11-16
CN1938276A (zh) 2007-03-28
EP1742922B1 (en) 2016-02-03
EA200601601A1 (ru) 2007-02-27
EA008697B1 (ru) 2007-06-29
MA28494B1 (fr) 2007-03-01
BRPI0509506A (pt) 2007-09-18
DK1742922T3 (en) 2016-04-11
CA2562104C (en) 2010-08-17
SI1742922T1 (sl) 2016-07-29
US20100093820A1 (en) 2010-04-15
WO2005095349A1 (en) 2005-10-13
ES2565409T3 (es) 2016-04-04

Similar Documents

Publication Publication Date Title
DK3724191T3 (da) 5-(2-(2,5-difluorphenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazol[1,5-a]pyrimidinderivater og lignende forbindelser som trk-kinasehæmmere til cancerbehandling
NO20072443L (no) Fungicide aktive ingredienskombinasjoner
NO20081631L (no) Lav hygroskopisk Aripiprazol medikament forbindelse og fremgangsmate for fremstilling derav
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
DK1713475T3 (da) 1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
NO20053546D0 (no) Triazolderivater som inhibitorer av 11-beta-hydroksysteroiddehydrogenase-1.
JOP20200194A1 (ar) صور بلورية جديدة
WO2008058285A3 (en) 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
TW200616965A (en) Synthesis of n2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents
WO2003076398A3 (en) Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
EP1638947A4 (en) TRIAZONE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1
PE20080545A1 (es) Isoxazolinas insecticidas
CA2471952A1 (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
IN2014DN08578A (no)
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
NZ798171A (en) Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1h-pyrazole-4-carboxamide
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
EA200300067A1 (ru) Кристаллическая форма целекоксиба
NO20064986L (no) Krystallin Pyrazolderivater
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
EP3747887A4 (en) MONOMETHANESULPHONATE CRYSTALLINE FORM OF A DEUTERATED COMPOUND OF 3- (4,5-SUBSTITUTE AMINOPYRIMIDINE) PHENYL, AND RELATED PREPARATION PROCESS
WO2003047517A3 (en) Novel-n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa
PE20071086A1 (es) DERIVADOS DE PIRAZOLOISOQUINOLINA COMO INHIBIDORES DE LA CINASA p38
WO2007069254A3 (en) POLYMORPHS AND AMORPHOUS FORMS OF 5-AMINO-l-[2,6- DICHLORO-4-(TRIFLUOROMETHYL)PHENYL]-4- [(TRIFLUOROMETHYL)SULFINYL]-IH-PYRAZOLE-3-CARBONITRILE